Neuroleptic Malignant Syndrome

Frederick E. Sieber; Alan J. Mcshane; Barry S. Fogel; Richard J. Goldberg; A. Shalev; H. Hermesh; D. Aizenberg; H. Munitz; Bruce M. Cohen; Ross J. Baldessarini; Harrison G. Pope; Joseph F. Lipinski; Barry H. Guzé; Lewis R. Baxter

doi:10.1056/NEJM198511143132015

Neuroleptic Malignant Syndrome

Frederick E. Sieber, Alan J. Mcshane, Barry S. Fogel, Richard J. Goldberg, A. Shalev, H. Hermesh, D. Aizenberg, H. Munitz, Bruce M. Cohen, Ross J. Baldessarini, Harrison G. Pope, Joseph F. Lipinski, Barry H. Guzé, Lewis R. Baxter

School of Medicine

Research output: Contribution to journal › Letter › peer-review

32 Scopus citations

Abstract

To the Editor: We were interested in the review of the neuroleptic malignant syndrome by Guzé and Baxter (July 18 issue).¹ However, as anesthesiologists we were rather perturbed by the suggestion that pancuronium or curare should be used to help distinguish malignant hyperthermia from it. This is not an accepted diagnostic maneuver in malignant hyperthermia. When the diagnosis of malignant hyperthermia is suspected (the main clue being that it usually occurs perioperatively in association with the administration of certain anesthetic drugs), it is immediately treated as such before it becomes fulminant. This consists of stopping volatile anesthetic agents, giving intravenous.

Original language	English (US)
Pages (from-to)	1292-1293
Number of pages	2
Journal	New England Journal of Medicine
Volume	313
Issue number	20
DOIs	https://doi.org/10.1056/NEJM198511143132015
State	Published - Nov 14 1985

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM198511143132015

Cite this

@article{ee2c97b26b244307b69c757c9ecca337,

title = "Neuroleptic Malignant Syndrome",

abstract = "To the Editor: We were interested in the review of the neuroleptic malignant syndrome by Guz{\'e} and Baxter (July 18 issue).1 However, as anesthesiologists we were rather perturbed by the suggestion that pancuronium or curare should be used to help distinguish malignant hyperthermia from it. This is not an accepted diagnostic maneuver in malignant hyperthermia. When the diagnosis of malignant hyperthermia is suspected (the main clue being that it usually occurs perioperatively in association with the administration of certain anesthetic drugs), it is immediately treated as such before it becomes fulminant. This consists of stopping volatile anesthetic agents, giving intravenous.",

author = "Sieber, {Frederick E.} and Mcshane, {Alan J.} and Fogel, {Barry S.} and Goldberg, {Richard J.} and A. Shalev and H. Hermesh and D. Aizenberg and H. Munitz and Cohen, {Bruce M.} and Baldessarini, {Ross J.} and Pope, {Harrison G.} and Lipinski, {Joseph F.} and Guz{\'e}, {Barry H.} and Baxter, {Lewis R.}",

year = "1985",

month = nov,

day = "14",

doi = "10.1056/NEJM198511143132015",

language = "English (US)",

volume = "313",

pages = "1292--1293",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "20",

}

TY - JOUR

T1 - Neuroleptic Malignant Syndrome

AU - Sieber, Frederick E.

AU - Mcshane, Alan J.

AU - Fogel, Barry S.

AU - Goldberg, Richard J.

AU - Shalev, A.

AU - Hermesh, H.

AU - Aizenberg, D.

AU - Munitz, H.

AU - Cohen, Bruce M.

AU - Baldessarini, Ross J.

AU - Pope, Harrison G.

AU - Lipinski, Joseph F.

AU - Guzé, Barry H.

AU - Baxter, Lewis R.

PY - 1985/11/14

Y1 - 1985/11/14

N2 - To the Editor: We were interested in the review of the neuroleptic malignant syndrome by Guzé and Baxter (July 18 issue).1 However, as anesthesiologists we were rather perturbed by the suggestion that pancuronium or curare should be used to help distinguish malignant hyperthermia from it. This is not an accepted diagnostic maneuver in malignant hyperthermia. When the diagnosis of malignant hyperthermia is suspected (the main clue being that it usually occurs perioperatively in association with the administration of certain anesthetic drugs), it is immediately treated as such before it becomes fulminant. This consists of stopping volatile anesthetic agents, giving intravenous.

AB - To the Editor: We were interested in the review of the neuroleptic malignant syndrome by Guzé and Baxter (July 18 issue).1 However, as anesthesiologists we were rather perturbed by the suggestion that pancuronium or curare should be used to help distinguish malignant hyperthermia from it. This is not an accepted diagnostic maneuver in malignant hyperthermia. When the diagnosis of malignant hyperthermia is suspected (the main clue being that it usually occurs perioperatively in association with the administration of certain anesthetic drugs), it is immediately treated as such before it becomes fulminant. This consists of stopping volatile anesthetic agents, giving intravenous.

UR - http://www.scopus.com/inward/record.url?scp=0022388674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022388674&partnerID=8YFLogxK

U2 - 10.1056/NEJM198511143132015

DO - 10.1056/NEJM198511143132015

M3 - Letter

C2 - 4058514

AN - SCOPUS:0022388674

SN - 0028-4793

VL - 313

SP - 1292

EP - 1293

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 20

ER -

Neuroleptic Malignant Syndrome

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this